AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival

Dow Jones01-17

By Kelly Cloonan

Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said.

AbbVie and Genmab said Friday the trial results also showed improvement in patients' complete response rate, duration of response and time to next treatment.

The study didn't demonstrate a statistically significant improvement in overall survival, however, the companies said.

The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant.

Further analysis of the results is continuing, the companies said.

Genmab and AbbVie plan to engage with global regulatory authorities to discuss next steps. The data will also be submitted for presentation at a future medical meeting, they said.

"The results from this global trial contribute to the growing body of evidence supporting epcoritamab," Genmab's Chief Executive Jan van de Winkel said.

Epcoritamab has previously received regulatory approval for certain lymphoma indications in more than 65 countries.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 16, 2026 14:10 ET (19:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604915642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 03:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604915642","market":"sg","top_or_hot":-1,"title":"AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. \n</p>\n<p>\n  AbbVie and Genmab said Friday the trial results also showed improvement in patients' complete response rate, duration of response and time to next treatment. \n</p>\n<p>\n  The study didn't demonstrate a statistically significant improvement in overall survival, however, the companies said. \n</p>\n<p>\n  The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant. \n</p>\n<p>\n  Further analysis of the results is continuing, the companies said. \n</p>\n<p>\n  Genmab and AbbVie plan to engage with global regulatory authorities to discuss next steps. The data will also be submitted for presentation at a future medical meeting, they said. \n</p>\n<p>\n  \"The results from this global trial contribute to the growing body of evidence supporting epcoritamab,\" Genmab's Chief Executive Jan van de Winkel said. \n</p>\n<p>\n  Epcoritamab has previously received regulatory approval for certain lymphoma indications in more than 65 countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 14:10 ET (19:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-17 03:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. \n</p>\n<p>\n  AbbVie and Genmab said Friday the trial results also showed improvement in patients' complete response rate, duration of response and time to next treatment. \n</p>\n<p>\n  The study didn't demonstrate a statistically significant improvement in overall survival, however, the companies said. \n</p>\n<p>\n  The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant. \n</p>\n<p>\n  Further analysis of the results is continuing, the companies said. \n</p>\n<p>\n  Genmab and AbbVie plan to engage with global regulatory authorities to discuss next steps. The data will also be submitted for presentation at a future medical meeting, they said. \n</p>\n<p>\n  \"The results from this global trial contribute to the growing body of evidence supporting epcoritamab,\" Genmab's Chief Executive Jan van de Winkel said. \n</p>\n<p>\n  Epcoritamab has previously received regulatory approval for certain lymphoma indications in more than 65 countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 14:10 ET (19:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965509101.SGD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2604915642","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604915642","pubTimestamp":1768590600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said.AbbVie and Genmab said Friday the trial results also showed improvement in patients' complete response rate, duration of response and time to next treatment.The study didn't demonstrate a statistically significant improvement in overall survival, however, the companies said.The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant.Genmab and AbbVie plan to engage with global regulatory authorities to discuss next steps. The data will also be submitted for presentation at a future medical meeting, they said.\"The results from this global trial contribute to the growing body of evidence supporting epcoritamab,\" Genmab's Chief Executive Jan van de Winkel said.Epco","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","ABBV":"艾伯维公司","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0861579265.USD":"联博低波幅策略股票基金A","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","GMAB":"Genmab A/S","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC"},"translate_title":"艾伯维、Genmab淋巴瘤治疗显示无进展生存期改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5,"GMAB":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. \n\n\n  AbbVie and Genmab said Friday the trial results also showed improvement in patients' complete response rate, duration of response and time to next treatment. \n\n\n  The study didn't demonstrate a statistically significant improvement in overall survival, however, the companies said. \n\n\n  The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant. \n\n\n  Further analysis of the results is continuing, the companies said. \n\n\n  Genmab and AbbVie plan to engage with global regulatory authorities to discuss next steps. The data will also be submitted for presentation at a future medical meeting, they said. \n\n\n  \"The results from this global trial contribute to the growing body of evidence supporting epcoritamab,\" Genmab's Chief Executive Jan van de Winkel said. \n\n\n  Epcoritamab has previously received regulatory approval for certain lymphoma indications in more than 65 countries. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 14:10 ET (19:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604915642","isCrawlerRequest":true}